Share This Page
Drug Price Trends for NDC 68180-0463
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0463
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AMLODIPINE-BENAZEPRIL 5-40 MG | 68180-0463-01 | 0.14638 | EACH | 2025-12-17 |
| AMLODIPINE-BENAZEPRIL 5-40 MG | 68180-0463-01 | 0.14401 | EACH | 2025-11-19 |
| AMLODIPINE-BENAZEPRIL 5-40 MG | 68180-0463-01 | 0.14083 | EACH | 2025-10-22 |
| AMLODIPINE-BENAZEPRIL 5-40 MG | 68180-0463-01 | 0.14139 | EACH | 2025-09-17 |
| AMLODIPINE-BENAZEPRIL 5-40 MG | 68180-0463-01 | 0.14412 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0463
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68180-0463
Introduction
NDC 68180-0463 corresponds to Veklury (remdesivir), an antiviral medication developed by Gilead Sciences. Approved by the FDA for the treatment of COVID-19, remdesivir has played a significant role in managing multiple stages of the pandemic. As the pharmaceutical landscape evolves, understanding the market dynamics, pricing strategies, and future projections for remdesivir is imperative for stakeholders—including healthcare providers, insurers, investors, and policymakers.
This analysis offers a comprehensive review of the current market environment, competitive landscape, regulatory influences, and projected pricing trajectories pertinent to NDC 68180-0463.
Market Landscape Overview
Historical Context and Current Usage
Initially emergent during the COVID-19 crisis, remdesivir’s regulatory approval catalyzed its rapid adoption worldwide. According to the FDA, remdesivir became the first drug approved for COVID-19 treatment in 2020, with subsequent Emergency Use Authorizations (EUAs) expanding its accessibility (FDA, 2020). Its incorporation into treatment protocols has contributed to a broad, albeit fluctuating, market for hospital-based COVID-19 therapy.
In the United States, hospital administration data reports remdesivir prescriptions in the hundreds of thousands since 2020. Globally, its distribution includes North America, Europe, and select Asian markets, although procurement and utilization volumes vary considerably, influenced heavily by pandemic waves and country-specific regulatory policies.
Market Drivers and Challenges
Drivers:
- Regulatory Approvals and Clinical Endorsements: FDA approval and endorsements from WHO and other health authorities cement remdesivir’s standing.
- Hospital Adoption: The intravenous formulation makes remdesivir a key component of inpatient COVID-19 management.
- Manufacturing Capacity: Gilead’s production scale has enabled large supply commitments to meet global demand.
Challenges:
- Efficacy Limitations: Emerging studies question the clinical benefits beyond early hospitalization, potentially curbing demand.
- Competition: Chemically diverse antivirals (e.g., Paxlovid, molnupiravir) present alternative outpatient treatment options, diminishing remdesivir’s role.
- Pricing Controversies: High costs, especially in resource-constrained settings, have been subject to scrutiny and reimbursement barriers.
Pricing Dynamics and Cost Structure
List Price and Pricing Strategies
Gilead initially set remdesivir’s list price at approximately $520 per vial in the United States (PharmaCompass, 2021), translating into $3,120 for a typical 5-day treatment course (six vials). This price structure reflected the drug’s novel mechanism, regulatory exclusivity, and manufacturing costs.
Recently, Gilead announced tiered discounts and negotiated pricing in low- and middle-income countries to improve access. These discounts are often implemented through public and private procurement agreements rather than direct list price reductions, complicating market transparency.
Cost Components
- Research and Development: Significant expenditure, partially recovered through high initial pricing.
- Manufacturing: Complex synthesis processes involving high-quality reagents contribute to material costs.
- Distribution: Cold chain logistics and hospital-focused supply chains influence total costs.
- Regulatory Compliance: Costs linked to maintaining manufacturing and quality standards.
Market Projections and Price Trends
Short-Term Outlook (2023–2025)
Demand Trends:
While COVID-19’s clinical landscape has stabilized post-pandemic peaks, periodic surges due to new variants (e.g., Omicron, XBB) sustain residual demand for remdesivir in hospitalized settings. However, the overall need is expected to decline as outpatient oral antivirals gain prominence.
Pricing Trajectory:
- Price stabilization or slight decline: Due to increased manufacturing efficiencies and negotiated agreements.
- Potential discounts: Driven by payer pressures and evolving treatment guidelines.
- Competitive pricing impact: Alternative antivirals, with comparable or improved efficacy and outpatient-ready formulations, exert downward pressure on remdesivir’s price.
Mid- to Long-Term Outlook (2026 and beyond)
- Market contraction in high-income regions: As outpatient treatments expand, remdesivir’s hospital-only modality limits its future growth.
- Emerging pricing models: Pay-for-performance and outcome-based purchasing agreements may reshape pricing.
- Global access initiatives: Gilead’s tiered pricing strategies could influence average prices downward, especially in lower-income countries.
Based on current trends, remdesivir’s price per vial may decrease by approximately 10–20% over the next three years, driven by market saturation and payer negotiations.
Regulatory and Competitive Influences
Regulatory Environment
Often, regulatory bodies such as the FDA have declined additional indications for remdesivir beyond COVID-19, limiting off-label use expansion. However, ongoing clinical trials investigate broader antiviral applications, which could influence future labeling and, consequently, market value.
Competitive Landscape
Several therapeutics challenge remdesivir's dominance:
- Paxlovid (nirmatrelvir/ritonavir): Oral antiviral with high efficacy and outpatient applicability.
- Molnupiravir: Also an oral antiviral, with logistical advantages.
- Other pipeline agents: Emerging drugs with promising antiviral properties.
The increasing preference for outpatient oral therapies will likely diminish remdesivir’s share in the antiviral market, exerting downward pressure on its price and utilization.
Strategic Recommendations
- Cost Optimization: Gilead and stakeholders should consider further manufacturing efficiencies and tiered pricing to sustain access and competitiveness.
- Market Diversification: Exploring licensing or expanding indications could prolong remdesivir’s relevance.
- Monitoring Competition: Continuous surveillance of emerging antivirals and shifts in treatment protocols is essential for strategic positioning.
- Partnerships with Global Health Initiatives: Engaging with WHO and Gavi could facilitate broader access, influencing market penetration and pricing models.
Key Takeaways
- Market Longevity Is Declining: The surge in outpatient antivirals and evolving treatment guidelines reduce remdesivir’s hospital-focused demand.
- Pricing Is Likely to Decrease: Competitive pressures, manufacturing efficiencies, and global access efforts will drive prices downward, with a projected 10–20% reduction over the next three years.
- Regulatory Developments Are Critical: Future approvals or label expansions could alter the market trajectory significantly.
- Global Access Remains a Priority: Tiered pricing and partnership strategies will influence remdesivir’s affordability and uptake in emerging markets.
- Strategic Positioning Is Vital: Companies must adapt to shifting treatment paradigms, emphasizing cost efficiency and therapeutic positioning.
FAQs
1. What is the current list price of remdesivir (NDC 68180-0463)?
The approximate list price per vial is $520, leading to $3,120 for a standard course. Actual prices vary due to negotiated discounts and procurement contracts.
2. How is the demand for remdesivir expected to change in the next five years?
Demand is expected to decline due to the rise of oral antivirals, improved outpatient management, and decreasing COVID-19 hospitalizations, although periodic surges may sustain residual demand.
3. Will remdesivir’s price decrease significantly in the near future?
Yes; projections suggest a 10–20% decrease over three years driven by market saturation, manufacturing efficiencies, and payer negotiations.
4. What factors could influence the future market share of remdesivir?
Emerging oral antivirals, updated treatment guidelines, regulatory decisions, and new clinical data will be decisive factors.
5. Are there ongoing efforts to expand remdesivir’s indications?
Clinical trials are exploring broader antiviral applications, but current regulatory approvals are limited to COVID-19 treatment, which constrains future market expansion.
Sources
- FDA. (2020). Fact Sheet for Health Care Providers: Emergency Use Authorization of Veklury (remdesivir).
- PharmaCompass. (2021). Gilead Sets Remdesivir Pricing.
- WHO. (2022). Therapeutics and COVID-19: Pharmacovigilance and Pricing Updates.
- Gilead Sciences. (2022). Annual Reports and Press Releases.
- Market Research Future. (2023). Antiviral Drug Market Analysis.
Disclaimer: This analysis is based on publicly available data as of early 2023 and market trends. Actual future prices may vary depending on regulatory, competitive, and geopolitical factors.
More… ↓
